Latest news with #Placebo
Metro
07-05-2025
- Entertainment
- Metro
70s rock star bans fans from using phones at upcoming shows
The guitarist of rock band Cold Chisel has announced fans will be barred from taking photos and recording during his tour. Ian Moss was one of the founding members of the Australian band, which came together in 1973 and was fronted by Jimmy Barnes. Their debut single Khe Sanh, released in 1978, is one of the most popular songs ever recorded by an Australian act. Although they disbanded in 1983, they've subsequently re-formed several times since then, the most recent being in 2012 when they also toured around the UK. In the decades since Ian, 70, has embarked on a successful solo career, with his 1989 debut album reaching number one on the Aria Albums Chart. This week he is hitting the road again for his latest tour, One Guitar One Night Only, but has now told fans they won't be able to use their phones at the gigs. Posting on Instagram, Ian explained the decision. 'To ensure the best possible experience for everyone – both the audience and the artists – photography and video recording will not be permitted during the performance,' he began. 'In the past, we've taken a relaxed approach, but following feedback about disruptions, we've changed our policy. Venue staff have been briefed and will help us enforce this policy. There will be no exceptions. 'We kindly ask you to respect the performers, fellow concertgoers, and the atmosphere by switching off phones and other devices for the duration of the show. Be present and enjoy the performance with your eyes.' Although some questioned the ban, the decision was largely met with support. 'While I think this is a cool move, I also think people should be allowed to record short 20 second videos of just their favourite songs! But I do still respect the decision made here,' Davis commented. 'Can't wait. What a great idea!' Laura shared. 'Having people videoing and shoving cameras up your nose is sort of putting when performing. Good call Ian,' Craig explained. 'This is objectively an improvement for concertgoers too, who don't want to watch the experience from behind the devices of those in the rows before them,' Joey added. Last year Bob Dylan announced he would be banning phones throughout his UK tour. The shows in London, Liverpool, Nottingham, Wolverhampton and Edinburgh, were phone-free, with people having to put their phones in a pouch, which closed automatically when in the venue and unlocked in the venue's concourse. At the time organisers said they hoped that by removing fans' ability to use phones, the concerts would be more 'in keeping with many past performances'. More Trending Two years earlier Placebo requested fans keep their phones in their pockets. 'It makes Placebo's performance so much more difficult,' they said. 'More difficult to connect with you and to communicate effectively the emotions of the songs. 'It is also disrespectful to your fellow concertgoers who want to watch the show, not the back of your phone.' Got a story? If you've got a celebrity story, video or pictures get in touch with the entertainment team by emailing us celebtips@ calling 020 3615 2145 or by visiting our Submit Stuff page – we'd love to hear from you. MORE: 70s rock icon granted his dying wish to be buried at sea MORE: Gloria Gaynor: 'The biggest misconception about me? That I'm a feminist' MORE: When is Eurovision 2025? Final date, UK entry, latest odds and more
Vogue
03-05-2025
- Entertainment
- Vogue
Hear Me Out: What If Gen Xers Are Actually the Cool Ones?
I am nine years old and my mother—in her mid-20s at the time—is vacuuming the living room while 'My Favourite Game' by the Cardigans plays on full blast. With each drum thwack she hits another corner with the power nozzle, bare feet padding across the carpet in low-rise jeans, me watching deadpan from the sofa. I will always associate that song with this memory. Sunlight splashing through the open window; those distorted vocals, turned up to full; and the big, blocky CD player, with speakers that make your hands shake if you touch them. Though I was born in the '90s—a millennial—I was raised by a dyed-in-the-wool Gen Xer, and was therefore spoonfed Gen-X culture from an early age. Our CD rack was full of '90s bands: Pixies, PJ Harvey, Placebo. The films I later became obsessed with were all of this era: Girl, Interrupted; Fallen Angels; Run Lola Run; Hackers. By the time I got into Bret Easton Ellis, Elizabeth Wurtzel's Prozac Nation, and Irvine Welsh—all Gen-X writers, with Gen-X sensibilities—something had become abundantly clear. I had been born 15 years or so too late. And now I was destined for a life of Instagram and Asos packages, as opposed to being a '90s slacker making mixtapes and hating on my corporate job. Over the past few years, generational warfare has only ramped up—so much so that it's become boring to even reference: Gen Z hating on millennials for being cringe, millennials hating on Gen Z for being puritanical, and everyone hating on boomers for being, well, boomers. But Gen X—born somewhere between 1965 and 1980—has been largely forgotten about (although even saying that has become a cliché of sorts). Alongside all of this finger-pointing among the generations are claims that, actually, we were the cool ones—no, it was me! But what if it's none of us? What if the cool ones are actually those unbothered people that nobody talks about?
Globe and Mail
07-04-2025
- Health
- Globe and Mail
Ulcerative Colitis Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
DelveInsight's, 'Ulcerative Colitis Pipeline Insight 2025' report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Ulcerative Colitis Pipeline Landscape. It covers the Ulcerative Colitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ulcerative Colitis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Ulcerative Colitis Treatment Landscape. Click here to read more @ Ulcerative Colitis Pipeline Outlook Key Takeaways from the Ulcerative Colitis Pipeline Report In April 2025, Merck Sharp & Dohme LLC announced a study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12. In April 2025, Janssen Research & Development, LLC announced a study is to evaluate the efficacy, including clinical remission of guselkumab subcutaneous (SC) induction compared to placebo in participants with moderately to severely active ulcerative colitis (UC). DelveInsight's Ulcerative Colitis pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Ulcerative Colitis treatment. The leading Ulcerative Colitis Companies such as Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Promising Ulcerative Colitis therapies such as VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others. Discover groundbreaking developments in Ulcerative Colitis therapies! Gain in-depth knowledge of key Ulcerative Colitis clinical trials, emerging drugs, and market opportunities @ Ulcerative Colitis Clinical Trials Assessment Ulcerative Colitis Emerging Drugs Profile Obefazimod: Abivax Obefazimod is an oral small-molecule drug candidate in clinical development for the treatment of moderately to severely active ulcerative colitis (UC) and has demonstrated anti-inflammatory activity in preclinical studies and in both Phase IIa and Phase IIb clinical trials. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ulcerative colitis. ABBV-668: AbbVie ABBV-668 is under development for the treatment of crohn's disease, unspecified immunological disorders and ulcerative colitis. The drug candidate acts by targeting receptor interacting serine/threonine protein kinase 1 (RIPK1). It is administered through oral route. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis. TEV-48574: Teva Pharmaceutical Anti-TL1A (TEV-'574) is a potentially best-in-class human IgG1 monoclonal antibody that targets tumor necrosis factor (TNF)-like ligand 1A (TL1A), also known as TNF superfamily member 15. TL1A signaling is believed to amplify inflammation and drives fibrosis associated with asthma and inflammatory bowel disease (IBD); thus, targeting TL1A with TEV-'574 may mitigate the over-active immune response in these conditions. Anti-TL1A (TEV-'574) is currently in Phase 2b clinical trials for the treatment of ulcerative colitis (UD) and Crohn's disease (CD), two types of inflammatory bowel disease. The safety and efficacy of anti-TL1A (TEV-'574) have not been reviewed by any regulatory authority. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ulcerative colitis. SOR102: Sorriso Pharmaceuticals SOR102 combines anti-TNF and anti-IL-23 vorabodies into a single dual-acting molecule a trypsin cleavable linker releases the monomers to independently engage their targets throughout intestinal tissue. SOR102 provides combination therapy locally within inflamed tissue with minimal risk of systemic immunosuppression. Overall benefits of dual targeting approach increased efficacy through blockade of different inflammatory mechanisms of IBD. Currently, the drug is in Phase I stage of its clinical trial for the treatment of ulcerative colitis. The Ulcerative Colitis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Ulcerative Colitis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ulcerative Colitis Treatment. Ulcerative Colitis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Ulcerative Colitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ulcerative Colitis market Stay informed about the Ulcerative Colitis pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Ulcerative Colitis Unmet Needs Ulcerative Colitis Companies Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Intra-articular Intraocular Intrathecal Intravenous Oral Parenteral Subcutaneous Topical Transdermal Ulcerative Colitis Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Transform your understanding of the Ulcerative Colitis Pipeline! See the latest progress in drug development and clinical research @ Ulcerative Colitis Market Drivers and Barriers, and Future Perspectives Scope of the Ulcerative Colitis Pipeline Report Coverage- Global Ulcerative Colitis Companies- Oppilan Pharma, Genentech, Teva Branded Pharmaceutical, Boehringer Ingelheim, Sorriso Pharmaceuticals, Reistone Biopharma, Celgene, AnaptysBio, Rise Therapeutics, Merck, AltruBio, AbbVie, Immunic AG, Kissei Pharmaceutical Co, Lmito Therapeutics, Morphic Therapeutic, Oncostellae, Palatin Technologies, and others. Ulcerative Colitis therapies- VE202, Vancomycin Oral Capsule, PL8177, Mirikizumab, Etrasimod, Efavaleukin alfa, ABBV-668, and others. Ulcerative Colitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Ulcerative Colitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III "Stay Ahead in Gastroenterology Research–Access the Full Ulcerative Colitis Pipeline Analysis Today! @ Ulcerative Colitis Drugs and Companies Table of Content Introduction Executive Summary Ulcerative Colitis: Overview Pipeline Therapeutics Therapeutic Assessment Ulcerative Colitis– DelveInsight's Analytical Perspective In-depth Commercial Assessment Ulcerative Colitis Collaboration Deals Late Stage Products (Preregistration) Mirikizumab: Eli Lilly and Company Drug profiles in the detailed report….. Late Stage Products (Phase III) Obefazimod: Abivax Drug profiles in the detailed report….. Mid Stage Products (Phase II) ABBV-668: AbbVie Drug profiles in the detailed report….. Early Stage Products (Phase I) SOR102: Sorriso Pharmaceuticals Drug profiles in the detailed report….. Preclinical Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Ulcerative Colitis Key Companies Ulcerative Colitis Key Products Ulcerative Colitis- Unmet Needs Ulcerative Colitis- Market Drivers and Barriers Ulcerative Colitis- Future Perspectives and Conclusion Ulcerative Colitis Analyst Views Ulcerative Colitis Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
The Independent
19-02-2025
- Entertainment
- The Independent
‘Nazi' jibe at Italian PM lands British rock star police charge
Placebo frontman Brian Molko has been charged with defamation after he reportedly called the Italian prime minister a 'fascist' and a ' Nazi ' during a gig in the country. Molko, 52, is said to have made the remarks about Giorgia Meloni when Placebo played the Sonic Park festival in Turin in 2023, which drew an attendance of around 5000 people. Italy 's justice ministry approved a request from prosecutors on Monday (17 February) to charge the Scottish-American rocker for allegedly calling Ms Meloni a 'piece of s***, fascist, racist' and a 'Nazi'. Local prosecutors responded to a complaint from police at the festival about Molko who was subsequently investigated for defamation and contempt. At the time, members of Meloni's far-right Brothers of Italy party, which has its roots in Italy's neo-fascist movement, denounced the insults and demanded an apology. 'We cannot let an international event that attracts so many people (to Italy) be ruined by filthy words which, amidst a general silence, aim to attack the institutions of the republic,' LaPresse quoted Brothers of Italy lawmaker Augusta Montaruli as saying. Defamation offences in Italy can land culprits with a prison term of up to three years. However, a spokesman for Justice Minister, Carlo Norio said that a sentence is unlikely to be imposed in this instance. Molko is now likely to face a fine of €5,000 (£4,200) if the charges are upheld. Meloni was elected in September 2022, after her far-right Brothers of Italy party won an overall majority. In July 2024 an Italian judge ordered a journalist to pay Meloni €5,000 (£4,210) in damages for mocking her height on social media, ruling that it amounted to 'body shaming'. Enjoy unlimited access to 100 million ad-free songs and podcasts with Amazon Music Sign up now for a 4 month free trial (3 months for non-Prime members) Sign up The judge also imposed a suspended fine of €1,200 on Giulia Cortese for her defamatory posts on X from 2021, before Ms Meloni took power. Ms Cortese reacted to the judgment saying the Italian government had a ' serious problem with freedom of expression and journalistic dissent '. 'This country seems to get closer to Orbán's Hungary,' she said on X. 'These are bad times for independent journalists and opinion leaders. Let's hope for better days ahead. We won't give up!' In October 2021, when Ms Meloni was still in opposition, Ms Cortese posted a digitally altered picture on X showing the politician standing in front of a bookshelf with a likeness of Benito Mussolini in the background.
Russia Today
19-02-2025
- Politics
- Russia Today
Rock star faces trial after calling Italian PM ‘fascist'
The lead singer of rock band Placebo, Brian Molko, has been charged with defamation by the Italian state after calling Prime Minister Giorgia Meloni a 'fascist,' media outlets reported on Tuesday. Meloni, who leads the national-conservative Brothers of Italy Party, sued Molko over comments he made in 2023. The 52-year-old British-American rock star branded the politician a 'fascist, racist' and 'piece of s**t' while performing at the Sonic Park music festival near the Italian city of Turin. He was charged with 'contempt of the institutions' shortly after prosecutors launched a probe into the claims in August 2023. On Monday, Italy's Justice Ministry reportedly authorized prosecutors in Turin to move forward with the legal proceedings. Molko is facing a fine and a direct summons to trial. Defaming the Italian government, parliament, courts, or army can carry a fine of up to €5,000 ($5,200). According to a spokesperson for Justice Minister Carlo Nordio, as cited by The Guardian, Molko is unlikely to receive a custodial sentence despite the fact that public defamation carries a prison term of up to three years in accordance with Italian law. Molko made the insults to a crowd of 5,000 people, a year after Meloni's party, which traces its heritage back to the Italian Socialist movement founded by allies of fascist dictator Benito Mussolini, secured victory in the 2022 elections. Meloni's anti-immigration stance and anti-LGBTQ views sparked criticism among the Italian opposition and political leaders across the EU. The case against Molko is not the first litigation launched by Meloni for defamation. Last year, the Italian prime minister won a lawsuit against a journalist who was ordered to pay her €5,000 for mocking her on social media. In 2023, the Italian writer Roberto Saviano was fined €1,000 for calling Meloni a 'bastard' while commenting on her views on immigration.
